Efficacy, Safety, Tolerability And Pharmacokinetics Of Tofacitinib For Treatment Of Systemic Juvenile Idiopathic Arthritis (Sjia) With Active Systemic Features In Children And Adolescent Subjects

Trial Profile

Efficacy, Safety, Tolerability And Pharmacokinetics Of Tofacitinib For Treatment Of Systemic Juvenile Idiopathic Arthritis (Sjia) With Active Systemic Features In Children And Adolescent Subjects

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Dec 2017 Planned End Date changed from 1 Apr 2023 to 6 Apr 2023.
    • 08 Dec 2017 Planned primary completion date changed from 1 Apr 2023 to 6 Apr 2023.
    • 08 Dec 2017 Planned initiation date changed from 1 Jan 2018 to 19 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top